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ABSTRACT 
 
Background and Objectives: Trans-placental transmission of parvovirus B19 during pregnancy can causes adverse out-
comes. Regarding its importance in prenatal care, we decided to study prevalence of parvovirus B19 infection among preg-
nant woman in Ardabil, Iran.
Materials and Methods: In a community based study with a cluster sampling, 350 pregnant women that attended in health 
care centers in Ardabil were selected. Serum samples were collected and Anti-B19 specific IgG was detected using com-
mercial enzyme-linked immunosorbent assays (Euroimmune Elisa kit, Germany). Furthermore, a questionnaire filled for all 
participants during samples collection.
Results: 64.6% (226/350) of participants were Ardabil citizen and the rest were from rural area (124/350). Anti-B19-spe-
cific IgG antibody was detected in 69.1% of pregnant women (242/350). Participants' ages ranged from 15 to 34 years with 
average of 23 years. According to our study, seroprevalence of IgG antibodies had positive significant correlation with the 
participants' age (r=0.268) but there were no significant relations between B19 seropositivity and living area, family member, 
number of commensals, number of living children, and the amount of hemoglobin (p>0.05). 
Conclusion:  Approximately, one-third of the participants were at risk of primary B19 infection. Therefore, health education 
of pregnant women and screening of infected pregnant women is recommended to prevent fetal complications.
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INTRODUCTION
Parvovirus B19 is a small, uncoated DNA virus 
belonging to the family Parvoviridae (1).  There are 
at least four types of parvovirus that infect human 
(2). Parvovirus B19 usually infects human through 
the respiratory system (3). Parvovirus B19 associates 
with a wide range of clinical symptoms and their pat-
tern is under effect of age and immune status of the 
host (4). Most of B19 infections are asymptomatic or 
only associate with mild non-specific illness. This 
virus can also be transmitted through blood trans-
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fusion and blood products (5). B19 infects humans 
widely and is almost endemic in all parts of the world 
(2).
Parvovirus B19 can also be transmitted through 
vertical transformation (from mother to fetus) (6). Its 
prevalence in pregnancy is about 1-5%, but in epi-
demic situation it receives to 10% (7-8).
Its incidence in pregnancy is about 1-5% and it 
can cause complications in 3% of infected pregnant 
women (9, 10). The virus is transmitted through ver-
tical transmission to the fetus and creates some com-
plications to fetus including anemia, spontaneous 
abortion, hydrops fetalis, intrauterine fetal death and 
congenital anomalies (11). Parvovirus infection of 
mothers is diagnosed using serologic or an Immune 
assay enzyme B19 IgM and B19 IgG (12). B19 IgG 
positive serologic evidence of previous infection 
with the virus that leads to lifelong immunity. In this 
study, we tried to determine prevalence of serum 
parvovirus infection in pregnant women and its asso-
ciation with some of the parameters such as number 
of lived children, number of family members, num-
ber of commensalts and amount of hemoglobin.
Infection during pregnancy can cause a variety 
of other signs of fetal damage. The risk of adverse 
fetal outcome increases if maternal infection occurs 
during the first two trimesters of pregnancy but may 
also happen during the third trimester. It is signifi-
cant cause of fetal loss throughout pregnancy, but 
has a higher impact in the second half of pregnancy 
when spontaneous fetal loss from other causes is rel-
atively rare (13). There are several risk factors about 
its infection in pregnant women. For example, the 
risk of infection in pregnant women with one child 
are 3 times more than nulliparous women, but this 
risk for women with three or more children are 7.5 
times more. The other risk factors are working in the 
school, care centers and other full stress jobs (14-16). 
Infection is more common during late winter and 
early spring (17). 
IgG antibody levels elevated with the increase of 
age (17, 18) at the age of 15, about 50% of persons 
have detectable IgG levels and its amount in older 
people, has increased to more than 90% (2).
The importance of B19 investigation in pregnant 
women is due to vertical transmission of this virus. 
The complications related to this virus are anemia, 
hydrops fetalis, fetal death, and unintended abortion 
(11). Intrauterine growth retardation, myocarditis, 
pleural effusion, pericardial effusion and brain in-
volvement of the fetus may occur following infection 
with the virus. Although, Parvovirus B19 is not re-
lated to congenital malformations (19, 20), in case of 
pregnant women infection, the prevalence of trans-
mision to the fetus is 30% (21).
Acute parvovirus B19 (B19V) infection is a proven 
risk for pregnant women and their fetus (22). Regard-
ing to complications related to B19 virus infection 
during pregnancy and lack of study about its infec-
tion prevalence in Ardabil County, this study was 
conducted with the aim of determination of the prev-
alence of parvovirus and IgG in pregnant women in 
Ardabil.
   
MATERIALS AND METHODS
 
   This study was conducted as a cross-sectional 
trial. The numbers of samples were calculated 350, 
based on statistical formula for sample size. These 
numbers were divided into 39 prenatal care centers, 
according to population covered by each center. 5 
ml of blood was taken from participant in care cen-
ters and was referred to the Reference Laboratory, 
immediately. The serum of blood samples were iso-
lated and were stored at -20 °C, until analysis. A 
questionnaire was filled at the time of sample collec-
tion. The questionnaire consisted of two parts: part 
I including mother's age, location, number of family 
members (father, mother, sister, brother), number of 
children, number of commensalts, and in Part II in-
formation about blood test of pregnant women, were 
recorded.
For measurement of IgG antibodies in serum 
samples against B19 virus, the ELISA kit Euroim-
mune, (Germany) was used as follows: 100 µl of se-
rum 1/201 diluted patients and 100 µl of each of the 
standards were added to micro plate wells in which 
the viral antigen was coated. The samples were  in-
cubated for 1 h at room temperature, then the wells 
were washed and 100 µl goat, anti-human, anti-IgG 
antibody binded to the peroxide was added to each 
sample and they kept at room temperature for one 
more hour. Then, after washing the wells, 100 µl of 
substrate (3, 3, 5, 5 ' tetra-methyl benzidine) was add-
ed to each well and allowed to create color within 30 
minutes at room temperature. Subsequently, 100 µl 
of fixing solution (sulfuric acid) was added to each 
well and a maximum light absorption of the double 
wavelengths of 450/630 nm were read using a plate 
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reader. Positive cases were recorded according to the 
kit instruction.
Data then coded and were statistically analyzed 
using SPSS v16 software. The Chi-square and T-test 
and descriptive methods were used for data analysis. 
The significant levels of 0.05 were used for all statis-
tical analysis.
In order to consider the principles of medical eth-
ics, information will be kept confidential and results 
are reported anonymously. Consent of the partici-
pants was taken, orally.
 
RESULTS
In this study, of 350 pregnant women, 64.6% 
(226/350) were Ardabil citizen and the rest were 
from rural area (124/350). The youngest participant 
was 15 years old and the oldest was 34 years (aver-
age of 23± 3.92 years). Participants in the study area, 
were divided into 4 age groups.
Overall, 242 (69.1%) had positive serology B19 IgG 
and 124 (30.9%) were seronegative.
Distributions of seroprevalence of parovirus B19 
among pregnant women in residence location are 
shown in Table 1. Of 108 people that living in rural 
areas, 85 (68.5%) were seropositive and 39 (31.5%) 
were negative. There was no significant relationship 
between residence location and prevalence of serum 
parvovirus B19 (p=0.475).
The average age of participants with positive serol-
ogy was 24.77±4.26 years, and the mean age of those 
with negative serology was 22.98±3.58 years. Result 
showed there was a significant correlation between 
age and the prevalence of parvovirus (r=0.268) and 
the immunity against the virus was higher in older 
pregnant women (Table 2).
The average number commensalts seropositive 
pregnant women was 3 ± 1.74 and those with nega-
tive serology 2.83 ± 1.16 that showed no significant 
relationship between the number of commensalts and 
prevalence of parvovirus (p=0.377).
The average family members of participants with 
positive serology was 6.86 ± 2.4 and those with neg-
ative serology was 6.61 ± 2.23, which showed no sig-
nificant relation between family size and prevalence 
of parvovirus (p=0.369) (Table 3).
The average number of lived children in partici-
pants those with positive serology was 0.57 ± 0.655 
and average number of lived children in those with 
Table 1. Distribution of serology parvovirus B19 prevalence 
among pregnant women based on residence location
Serology
Location
Urban
Rural
Total
Positive
157(69.5%)
85(68.5%)
242(69.1%)
Negative
69(30.5%)
39(31.5%)
108(30.9%)
Total
226(64.6%)
124(30.4%)
350(100%)
Table 2. Distribution of serology parvovirus B19 preva-
lence among pregnant women according to age group 
Serology
Age group
15-19 years
20-24 years
25-29 years
30-34 years
Total
Positive
37(67.27%)
67(56.77%)
107(74.8%)
31(91.1%)
242(100%)
Negative
18(32.73%)
51(43.23%)
36(25.2%)
3(8.9%)
108(100%)
Total
55(15.71%)
118(31.71%)
143(40.28%)
34(9.71%)
305(100%)
negative serology was 0.51 ± 0.634 which pre-
sented the relationship between family size and 
sero prevalence of Parvovirus was insignificant 
(p=0.417). 
The average amount of hemoglobin in participants 
with positive serology was 12.5±1.12 (p=0.177) and 
the average amount of hemoglobin in those with 
negative serology was 12.26±1.06 (p=0.169) which 
showed no significant relationship between hemo-
globin and serum parvovirus. 
DISCUSSION
   Results of this study showed that the prevalence of 
B19 in pregnant women in Ardabil was 69.1%. The 
result indicates high prevalence of this virus in Ard-
abil region. Similar results was reported by others. Zi-
yaeyan et al. (2005) in Shiraz showed that Parvovirus 
infection providence was 69.01% (17). In a cross-sec-
tional study, Sohrabi et al. (2007) reported that 55.7% 
of pregnant women referred to Ahvaz Imam Kho-
meini hospital were B19 positive (had specific IgG 
of B19). According to their findings, more than 40% 
of pregnant women had not IgG B19 and were at the 
risk of the virus infection and its fetus complications 
(23). In a study conducted in Nigeria by Emiasegen 
et al. (2011) parvovirus infection prevalence among 
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pregnant women attending to prenatal care clinics 
and its relation to occupation, number of children 
and transfusion history were studied. They reported 
that 273 pregnant women were studied and 27.5% 
of them had IgG antibody for B19 and the relation-
ship between the numbers of living children, occupa-
tion and achieved transfusion history were significant 
(24). 
   In another study, Elnifro (2009) found that its prev-
alence in Libya was 69% (25). These studies are in 
agreement with our findings. On the other hand, 
Khameneh (2014) reported that in Orumiyeh preva-
lence of parvovirus was 75.6% (26), that was further 
from the results of our study. Some researcher report-
ed lower prevalence. For example, Sohrabi in a study 
in Ahvaz showed that its incidence was 55.7% (19); 
Abiodun (2013) reported 20% in Nigeria (27), and 
Cohen (1995) declared 53% of pregnant women are 
immune to the virus (28).
   The difference between rural and urban areas in the 
prevalence of B19 virus was not significant. Of 226 
people lived in Urban area, 157 patients (69.5%) were 
positive while 68.5% of people (85 of 108) lived in 
rural areas were positive in serology.
  Mode of seropositive was observed in the 30-34 
years age group. The significance of difference among 
mean age between positive serology and negative se-
rology indicates that relationship between age and the 
prevalence of parvovirus. Therefore, its incidence was 
higher in older women.
  In the Ziyaeyan (2005) and Sohrabi (2007) studies, 
there was no significant correlation between age and 
the prevalence of parvovirus, that is contrast to our 
results (17,23). 
   In this study, the relations between seropositive in-
cidences with number of children, number of family 
members, number of commensalts, and hemoglobin 
content were not significant. This result is in agree-
Table 3. Relationship between the number of people breaking bread together, family size and the number of children living 
with an outbreak of Parvovirus B19
Variable
No. of Commensalt
No. of family members
No. of Lived Children
Serology
positive
negative
positive
negative
positive
negative
Mean (person)
3
2.83
6.86
6.61
0.57
0.51
Standard Deviation
1.74
1.16
2.40
2.23
0.655
0.634
P Value
0.377
0.369
0.417
ment with the results of Shahraki et al. (2001) (29). In 
a study from Nigeria, Emiasegen et al. (2011) showed 
that the number of children was related to the outbreak 
of parvovirus (24) that is not consistent with the re-
sults of our study.
   Comparison between the average number of sero-
positive children and seronegatives revealed that the 
number of children didn’t related to the prevalence of 
parvovirus that is in accordance with the Shahraki et 
al. (2001) (29).
   In a study of Emiasegen et al. in Nigeria the relation 
between the number of children and outbreak of par-
vovirus was significant (24) that is not consistent with 
our results.
CONCLUSION
   The results of this study showed a high susceptibil-
ity of pregnant women to parvovirus B19 in Ardabil 
region and immunity to the virus increases with age. 
In our study, a significant correlation was not found 
between the prevalence of parvovirus and the number 
of living children, number of family member, number 
of commensalts and hemoglobin content.
   Considering that a high percentage of infected preg-
nant women with Parvovirus B19 in the Ardebil re-
gion, health education and screening for the virus, 
especially in pregnant women with anemia is recom-
mended to prevent fetal complications.
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